LixiLan

Pharma

It's on: Sanofi diabetes combo recovers lead as FDA delays Novo med

Novo Nordisk’s combination diabetes drug didn’t lap Sanofi’s after all. Two weeks after the FDA put off approval of the French drugmaker’s insulin-plus-GLP-1 combo, the agency has pushed back Novo’s, too.

Tracy Staton Sep 6, 2016 7:39am

FDA thwarts Sanofi's attempt to beat Novo combo to market

Aug 21, 2016 7:29pm

For Sanofi's GLP-1 combo LixiLan, the whole works better than its parts

Jun 12, 2016 3:40pm